•Indian Pharma sector likely to grow 11%
over the years.
•Optimum regulatory situation & patent
regime is getting established.
•Increased revenue growth.
•India is currently the fifth largest
emerging market in the world today
with ~$9 bn of sales in 2010
INDIA AS AN EMERGING MARKET
•Doubling the disposable income and the number of
middle class households
•Expansion of medical infrastructure
•Penetration of health insurance
•Rising prevalence of chronic diseases
•Adoption of product patents
Aggressive market penetration driven by
On 21 May 2010, Abbott Laboratories
announced the acquisition of the Piramal
For an up-front payment of US$2.12 billion.
In addition to this, Abbott will also pay
US$400 million annually
for the next four years, beginning in 2011.
► Abbott is a global health care company
engaged in the discovery, development,
manufacture and marketing of pharmaceuticals
and medical products.
►Piramal Healthcare Solutions is a MUMBAI
based leading provider of Indian branded
generics, with a portfolio of around 350
products, including therapeutic areas such as
antibiotics, respiratory diseases, diabetes and
Abbott is following a Emerging
market penetration strategy.
Near saturation of the western
market is bringing MNCs to India.
This deal would help them give
an edge over their competitors.
Added attraction: In
India, individuals and not govt pay
for a big portion of the health care
► According to the terms of the agreement,
Abbott will obtain access to Piramal's
manufacturing facilities in Baddi in Himachal
Pradesh as well as the rights to sell more than
350 brands in the domestic market .
► Around 5,000 employees of Piramal's
Healthcare Solutions will now become part
which will take Abbott’s headcount to 7,500
► Piramal Healthcare will retain its Custom
Manufacturing business, its Critical Care
► Abbott could become the leading
pharmaceutical company in India
deal, Healthcare Solutions and Abbott’s
businesses will cumulatively become the
leader in India